UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies

Gynecologic oncology, 2012-04, Vol.125 (1), p.48-53

2012

Volltextzugriff (PDF)

Predicting everolimus/letrozole treatment efficacy in patients with advanced or recurrent endometrial cancer: A biomarker study

Gynecologic oncology, 2014-06, Vol.133, p.174-174

2014

Volltextzugriff (PDF)

Analyzing the learning curve of robotic-assisted sentinel lymph node dissection for endometrial cancer

Gynecologic oncology, 2014-06, Vol.133, p.130-130

2014

Volltextzugriff (PDF)

Does ultrastaging improve detection of micrometastasis for early-stage endometrial cancer?

Gynecologic oncology, 2014-06, Vol.133, p.130-131

2014

Volltextzugriff (PDF)

Impact of molecular testing in clinical practice of gynecologic cancers

Gynecologic oncology, 2018-06, Vol.149 (3), p.628-628

2018

Volltextzugriff (PDF)

Prevalence of high risk non-vaccine type HPV among U.S. women who received Cervarix or Gardasil: NHANES 2009-2014

Gynecologic oncology, 2018-06, Vol.149, p.204-205

2018

Volltextzugriff (PDF)

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)

Gynecologic oncology, 2023-07, Vol.174, p.278-287

2023

Volltextzugriff (PDF)

740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Annals of oncology, 2023-10, Vol.34, p.S507-S507

2023

Volltextzugriff (PDF)

VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Annals of oncology, 2023-05, Vol.34 (5), p.500-501

2023

Volltextzugriff (PDF)

Racial and ethnic disparities among patients with low-grade serous ovarian carcinoma

Gynecologic oncology, 2019-06, Vol.154, p.122-122

2019

Volltextzugriff (PDF)

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Annals of oncology, 2024-08, Vol.35 (8), p.728-738

2024

Volltextzugriff (PDF)

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Annals of oncology, 2023-11, Vol.34, p.S1586

2023

Volltextzugriff (PDF)

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Annals of oncology, 2023-10, Vol.34, p.S1276-S1277

2023

Volltextzugriff (PDF)

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

Gynecologic oncology, 2018-06, Vol.149, p.2-2

2018

Volltextzugriff (PDF)

New use of triptolide for endometrial cancers and evaluating effectiveness in platinum resistance in vitro

Gynecologic oncology, 2018-06, Vol.149 (3), p.626-626

2018

Volltextzugriff (PDF)

Hormonal receptor expression and clinical outcome in ovarian high-grade serous carcinoma

Gynecologic oncology, 2019-06, Vol.154, p.73-73

2019

Volltextzugriff (PDF)

Delays in definitive treatment for locally advanced cervical cancer: An analysis of disparities among a South Florida population between a university cancer center and a safety net hospital

Gynecologic oncology, 2019-06, Vol.154, p.133-133

2019

Volltextzugriff (PDF)

Mismatch repair (MMR) screening among minority women with endometrial cancer

Gynecologic oncology, 2019-06, Vol.154, p.108-108

2019

Volltextzugriff (PDF)

352: Laparoscopic Extraperitoneal Lymph Node Dissection in Patients With Locally Advanced Cervical Cancer: A Pilot Study

Journal of minimally invasive gynecology, 2007, Vol.14 (6), p.S128-S128

2007

Volltextzugriff (PDF)

Shifts in Practice Patterns: Addressing Disparities in Ovarian Cancer Care

Gynecologic oncology, 2017-10, Vol.147 (1), p.196-197

2017

Volltextzugriff (PDF)

Identifying disparities in germline and somatic testing in patients with ovarian cancer in a university health system

Gynecologic oncology, 2018-06, Vol.149, p.134-134

2018

Volltextzugriff (PDF)

Fallopian tube cells from high-risk women have altered adipokine signaling

Gynecologic oncology, 2018-06, Vol.149, p.72-72

2018

Volltextzugriff (PDF)

Examining the utility of magnetic resonance imaging compared with physical exam in cervical cancer staging

Gynecologic oncology, 2019-06, Vol.154, p.119-119

2019

Volltextzugriff (PDF)

Examining the utility of magnetic resonance imaging compared with physical exam in cervical cancer staging

Gynecologic oncology, 2019-06, Vol.153 (3), p.e5-e5

2019

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Obstetrics And Gynecology
(7)
Oncology
(6)
Endometrial Cancer
(4)
Female
(4)
Hematology, Oncology And Palliative Medicine
(4)
Humans
(4)
Life Sciences & Biomedicine
(4)
Obstetrics & Gynecology
(4)
Science & Technology
(4)
Adult
(3)
Middle Aged
(3)
Retrospective Studies
(3)
Aged
(2)
Neoplasm Staging
(2)
Pelvis
(2)
Stage Iii
(2)
Staging
(2)
Surgery
(2)
Access
(1)
Adenocarcinoma - Epidemiology
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Gynecologic Oncology
(20)
Annals Of Oncology
(7)
International Journal Of Gynecological Cancer
(5)
Journal Of Minimally Invasive Gynecology
(2)
Breast Diseases
(1)
Esmo Open
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies

Predicting everolimus/letrozole treatment efficacy in patients with advanced or recurrent endometrial cancer: A biomarker study

Analyzing the learning curve of robotic-assisted sentinel lymph node dissection for endometrial cancer

Does ultrastaging improve detection of micrometastasis for early-stage endometrial cancer?

Impact of molecular testing in clinical practice of gynecologic cancers

Prevalence of high risk non-vaccine type HPV among U.S. women who received Cervarix or Gardasil: NHANES 2009-2014

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)

750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial

740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

VP2-2023: Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Racial and ethnic disparities among patients with low-grade serous ovarian carcinoma

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

New use of triptolide for endometrial cancers and evaluating effectiveness in platinum resistance in vitro

Hormonal receptor expression and clinical outcome in ovarian high-grade serous carcinoma

Delays in definitive treatment for locally advanced cervical cancer: An analysis of disparities among a South Florida population between a university cancer center and a safety net hospital

Mismatch repair (MMR) screening among minority women with endometrial cancer

352: Laparoscopic Extraperitoneal Lymph Node Dissection in Patients With Locally Advanced Cervical Cancer: A Pilot Study

Shifts in Practice Patterns: Addressing Disparities in Ovarian Cancer Care

Identifying disparities in germline and somatic testing in patients with ovarian cancer in a university health system

Fallopian tube cells from high-risk women have altered adipokine signaling

Examining the utility of magnetic resonance imaging compared with physical exam in cervical cancer staging

Examining the utility of magnetic resonance imaging compared with physical exam in cervical cancer staging

Suchergebnisse filtern